List of Excipients in Branded Drug IBUTILIDE FUMARATE

« Back to Dashboard

Generic Drugs Containing IBUTILIDE FUMARATE

Company	Ingredient	NDC	Excipient
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ibutilide fumarate	23155-326	HYDROCHLORIC ACID
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ibutilide fumarate	23155-326	SODIUM ACETATE
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ibutilide fumarate	23155-326	SODIUM CHLORIDE
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ibutilide fumarate	23155-326	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in IBUTILIDE FUMARATE?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
2	SODIUM ACETATE
2	SODIUM CHLORIDE
2	SODIUM HYDROXIDE

Ibutilide Fumarate Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Ibutilide fumarate is a narrow-market, hospital-administered intravenous antiarrhythmic used for rapid conversion of atrial fibrillation and atrial flutter. Its commercial opportunity is concentrated in sterile injectable supply, generic reliability, hospital formulary access, and differentiated ready-to-administer packaging rather than in novel excipient chemistry.

The approved product, Corvert, is a simple aqueous formulation containing ibutilide fumarate, sodium chloride, and water for injection, with pH adjustment as needed. The formulation has limited excipient complexity, but manufacturing risk remains high because the product is a low-volume sterile injectable with clinically important QT-prolongation and torsades de pointes risks. [1]

What is the approved ibutilide fumarate formulation?

Ibutilide fumarate injection is supplied at a concentration of 0.1 mg/mL. The reference product is available in 10-mL vials containing 1 mg of ibutilide fumarate. The labeled formulation uses sodium chloride for tonicity and water for injection as the vehicle. Hydrochloric acid or sodium hydroxide may be used for pH adjustment. [1]

Formulation attribute	Reference-product profile
Active ingredient	Ibutilide fumarate
Dosage form	Sterile intravenous injection
Strength	0.1 mg/mL
Typical vial	1 mg in 10 mL
Primary vehicle	Water for injection
Tonicity agent	Sodium chloride
pH adjustment	Hydrochloric acid and/or sodium hydroxide
Administration	Intravenous infusion
Primary setting	Hospital or monitored acute-care facility
Regulatory category	Small-molecule prescription drug

The fumarate is the active pharmaceutical ingredient salt, not a discretionary functional excipient. The excipient system is intentionally minimal because ibutilide is administered intravenously and requires a clear, sterile, parenterally acceptable solution.

Which excipients are most important for ibutilide fumarate injection?

Sodium chloride

Sodium chloride provides isotonicity and supports intravenous tolerability. It is the main formulation excipient beyond the active salt. Its concentration must be controlled against osmolality, renal tolerability, container compatibility, and dilution instructions.

A commercial manufacturer should not assume that increasing sodium chloride concentration creates meaningful product differentiation. The more relevant objective is consistent osmolality across the labeled shelf life and after any permitted dilution.

Water for injection

Water for injection is the principal solvent. Control of endotoxin, bioburden, particulate matter, dissolved gases, and conductivity is critical. Since the formulation is aqueous and low in excipient content, changes in water quality can directly affect product quality.

pH adjusters

Hydrochloric acid and sodium hydroxide may be used to achieve the target pH. pH control can affect:

• Ibutilide chemical stability
• Formation of visible or subvisible particles
• Container-closure compatibility
• Extractables and leachables
• Dilution stability
• Patient tolerability

The finished-product pH should be established through development studies rather than inferred from the reference label. A narrow pH range may improve stability but increase manufacturing sensitivity. A wider range can simplify manufacturing but create greater batch-to-batch variation.

What excipient strategy is appropriate for a generic ibutilide product?

The lowest-risk strategy is to remain qualitatively and quantitatively close to the reference formulation. A generic developer should generally prioritize:

1. Sodium chloride and water for injection as the core excipient system.
2. Minimal pH adjustment with hydrochloric acid or sodium hydroxide.
3. A vial and stopper system with demonstrated compatibility.
4. Low extractables and leachables.
5. A validated sterilization and aseptic-processing design.
6. Clear evidence of equivalence in assay, impurities, pH, osmolality, sterility, endotoxins, and particulate matter.

A more complex formulation could create regulatory and technical burdens without producing a meaningful clinical benefit. Preservatives are generally unattractive for an intravenously administered antiarrhythmic supplied in single-dose packaging. Surfactants, antioxidants, chelators, and nonaqueous cosolvents would require a strong stability rationale and could complicate the ANDA or 505(b)(2) pathway.

Potential excipient development options

Strategy	Commercial value	Main risk
Reference-like sodium chloride solution	High for generic entry	Limited differentiation
Preservative-free single-dose vial	High for hospital use	Sterile manufacturing cost
Ready-to-use premixed bag	Moderate to high	Stability, shipping, and device validation
Prefilled syringe	Moderate	Compatibility, labeling, and dose-volume issues
Alternative buffer system	Low to moderate	May trigger formulation and equivalence questions
Antioxidant or chelator	Low unless degradation is demonstrated	New impurity and safety burden
Lyophilized presentation	Low	More complex manufacturing for an already aqueous product

What manufacturing and formulation barriers affect ibutilide fumarate?

The principal barriers are sterile manufacturing, low annual volume, quality-system overhead, and product liability exposure. The formulation itself is simple, but injectable products require validated control of sterility, endotoxins, particulate matter, container closure, and filling accuracy.

Ibutilide presents an additional safety challenge. The product can prolong the QT interval and cause torsades de pointes. The FDA label requires continuous ECG monitoring during administration and for a defined post-treatment period. [1] Packaging, labeling, and preparation instructions therefore have a direct risk-management role.

Container-closure selection

Glass vials are the most conservative commercial option. A developer should evaluate:

• Type I glass compatibility
• Stopper extractables and leachables
• Adsorption of ibutilide or related substances
• Headspace oxygen
• Light exposure
• Container closure integrity
• Performance after shipping and temperature excursions

Polymer containers or prefilled systems could reduce handling steps, but they require more extensive interaction studies. The product’s low concentration makes adsorption and recovery testing important, particularly for syringes, tubing, and administration sets.

Sterility and terminal processing

A terminally sterilized product could offer a stronger sterility assurance profile if formulation stability permits. If terminal sterilization is unsuitable, aseptic processing must be supported by media fills, validated filtration, environmental monitoring, and robust container-closure integrity testing.

A developer should compare terminal sterilization and aseptic filling early. The commercial decision depends on degradation under heat, impurity growth, container performance, and achievable shelf life.

What FDA regulatory status applies to ibutilide fumarate?

Ibutilide fumarate was approved in the United States as Corvert injection under NDA 20-885. The product is an established small-molecule injectable, not a biologic. Generic development would ordinarily proceed through an abbreviated new drug application if the applicant can demonstrate pharmaceutical equivalence and bioequivalence through the applicable FDA framework. [1,2]

Because ibutilide is administered intravenously as an aqueous solution, an in vivo clinical bioequivalence study may not be necessary when the generic product meets the relevant sameness criteria. The regulatory burden remains substantial for injectable quality attributes, including sterility, endotoxins, particulate matter, impurities, pH, assay, osmolality, and container closure.

FDA exclusivity and Orange Book status

The original product’s statutory exclusivity periods have expired. Any commercial protection would therefore depend primarily on patents, manufacturing capability, regulatory approval, supply reliability, contracting, and hospital purchasing relationships.

The FDA Orange Book should be reviewed for current listed patents associated with the reference product and any later-approved presentations. The principal commercial question is whether an active, enforceable formulation, method-of-use, or device patent remains listed. Historical approval alone does not establish current patent protection. [2]

What patents protect ibutilide fumarate?

Ibutilide’s original composition-of-matter and development patents are historical assets rather than a clear barrier to generic entry. The commercially relevant patent categories would be:

• Ibutilide or ibutilide fumarate composition claims
• Injectable formulation claims
• Treatment claims for conversion of atrial fibrillation or atrial flutter
• Dosing or infusion-time claims
• Container or delivery-device claims
• Manufacturing and purification claims

For a generic applicant, the main diligence point is not the existence of old ibutilide patents but whether any unexpired patent is listed in the Orange Book or enforceable under applicable national law. Publicly available product information establishes the approved formulation and clinical use, but it does not by itself establish a current blocking patent estate.

When does ibutilide fumarate lose exclusivity?

Commercial exclusivity has already expired for the original Corvert product. Ibutilide is therefore an off-patent small molecule in a mature therapeutic category. The timing of generic entry depends on the status of approved ANDAs, current market supply, and any remaining listed patents rather than on new chemical-entity exclusivity.

The product has no biosimilar pathway because ibutilide is a chemically synthesized small molecule. Competitors would enter through generic drug applications, not biosimilar applications.

Which companies are challenging ibutilide fumarate?

Ibutilide is not a high-volume product with a highly visible patent-challenge market. Publicly prominent Paragraph IV litigation is limited compared with products such as major cardiovascular blockbusters, oncology drugs, or biologics.

A prospective entrant should examine:

• FDA-approved ANDA listings
• Orange Book patent certifications
• Federal district court docket records
• FDA drug shortage data
• National wholesaler availability
• Hospital purchasing contracts
• Product discontinuation notices

The practical competitive challenge is likely to be market access and reliable supply rather than an extended patent dispute.

What generic launch risks exist for ibutilide fumarate?

Low-volume economics

Ibutilide is used selectively in monitored hospital settings. Annual demand is constrained by clinical alternatives, including electrical cardioversion, amiodarone, and other rhythm-control strategies. Small volumes reduce manufacturing scale and can make a single supplier economically important.

Safety-related demand constraints

The drug requires ECG monitoring and carries a risk of serious ventricular arrhythmia. These requirements narrow use to institutions with appropriate monitoring capacity. The safety profile limits expansion through consumer-facing or outpatient channels.

Shortage exposure

A small supplier base, low-margin injectable economics, and sterile manufacturing disruptions can create shortage opportunities. A supplier with redundant API sourcing, validated alternate fill-finish capacity, and inventory discipline can win hospital business even without a new excipient technology.

Substitution risk

Hospital formularies may favor other antiarrhythmics or electrical cardioversion. A generic ibutilide product must therefore compete on availability, contract pricing, vial utilization, and pharmacy workflow.

What commercial opportunities exist for ibutilide fumarate?

Reliable generic injectable supply

The clearest opportunity is a dependable generic product with consistent availability. Hospitals and group purchasing organizations place high value on continuity for acute-care injectables. A manufacturer can differentiate through:

• Dual-source API strategy
• U.S. or European fill-finish capacity
• Safety stock
• Smaller minimum order quantities
• Predictable allocation policies
• Rapid shortage response

Ready-to-use presentations

A ready-to-use infusion bag or pharmacy-prepared presentation could reduce compounding steps and medication-preparation errors. This opportunity must be tested against the small market size and stability requirements.

A premixed presentation would need data on:

• Long-term and accelerated stability
• Administration-set compatibility
• Adsorption and recovery
• Particulate formation
• Light exposure
• Shipping vibration and temperature excursions
• In-use stability

The commercial value would be greatest in hospitals with centralized pharmacy operations and high medication-safety requirements.

Prefilled syringe or dose-specific packaging

A 1-mg dose in a ready-to-administer syringe could reduce preparation time. However, the dose may not be universal across patient weight categories, and the product is generally administered under physician-directed hospital protocols. Syringe development is therefore a workflow opportunity, not an obvious market-wide replacement for vials.

Contract manufacturing and private-label supply

An established sterile manufacturer could supply ibutilide fumarate for another pharmaceutical company under a private-label or licensing arrangement. The asset is more attractive as part of a broader hospital injectable portfolio than as a standalone launch.

Geographic expansion

Demand may exist in markets where atrial fibrillation treatment pathways use pharmacologic cardioversion and where reliable sterile injectable supply is limited. Registration strategy should assess:

• Local treatment guidelines
• Hospital procurement systems
• Existing branded and generic suppliers
• Local pharmacovigilance requirements
• Packaging and language rules
• Cold-chain or ambient-storage conditions
• Patent status by jurisdiction

United States, European, Canadian, Australian, and selected emerging-market opportunities should be evaluated separately. Patent expiry in one country does not establish freedom to operate in another.

How strong is the ibutilide fumarate patent estate?

The patent estate is commercially weak relative to active, protected specialty drugs because the original product is mature and its exclusivity period has expired. The most defensible remaining value is likely to reside in manufacturing know-how, sterile-process validation, packaging, supply agreements, and regulatory execution.

Asset category	Likely commercial strength
Original active-ingredient patents	Low after expiry
New chemical entity exclusivity	Expired
Basic aqueous formulation	Low
Hospital-use method patents	Low to moderate, subject to claim scope
Ready-to-use packaging	Moderate if claims are valid and narrow
Manufacturing process know-how	Moderate
Sterile supply capability	High practical value
Hospital contracts and distribution	High practical value

How does ibutilide compare with competing antiarrhythmics?

Product	Primary use	Administration	Main commercial constraint
Ibutilide fumarate	Rapid pharmacologic conversion of atrial fibrillation/flutter	IV	QT prolongation and monitoring
Amiodarone	Rhythm control across several arrhythmias	IV and oral	Toxicity, prolonged use, complex profile
Dofetilide	Rhythm maintenance or conversion in selected patients	Oral	Initiation requires monitored hospitalization
Electrical cardioversion	Rapid rhythm conversion	Procedure	Anesthesia, equipment, and staffing
Flecainide or propafenone	Selected patients without structural heart disease	Oral	Patient-selection limitations

Ibutilide’s commercial position depends on the need for rapid pharmacologic conversion without a procedure, balanced against monitoring requirements and torsades risk. It is a focused product, not a broad cardiovascular platform.

Key Takeaways

• Ibutilide fumarate injection uses a simple excipient system centered on sodium chloride and water for injection.
• The best generic formulation strategy is close to the reference product, with minimal excipient innovation.
• The main technical risks are sterile processing, pH control, impurities, particulates, container compatibility, and shelf-life performance.
• Original product exclusivity has expired, and the product has no biosimilar pathway.
• Current Orange Book and litigation review is required to confirm any remaining listed patent or Paragraph IV activity.
• The strongest commercial opportunity is reliable hospital supply, not a novel excipient platform.
• Ready-to-use bags, prefilled syringes, and private-label sterile supply could provide selective differentiation.
• Manufacturing resilience, packaging validation, and hospital contracting are likely to create more value than formulation complexity.

FAQs About Ibutilide Fumarate Excipient and Commercial Strategy

Is sodium chloride required in ibutilide fumarate injection?

The reference product uses sodium chloride to support isotonicity. A developer may use another tonicity strategy only with adequate pharmaceutical, safety, stability, and regulatory justification.

Can ibutilide fumarate be supplied in a prefilled syringe?

Yes, a prefilled syringe is technically possible, but it requires validation of syringe materials, adsorption, extractables and leachables, dose accuracy, sterility, container closure, and administration compatibility.

Does ibutilide fumarate require refrigeration?

Storage conditions must follow the approved product labeling for the specific manufacturer. A new product cannot rely on the reference label without its own stability data and approved storage specification.

Is ibutilide fumarate a candidate for 505(b)(2) development?

A conventional equivalent injectable would usually be evaluated through the generic pathway. A 505(b)(2) strategy could become relevant for a materially different delivery system, formulation, dose presentation, or administration method.

What is the highest-value ibutilide fumarate product concept?

A dependable, preservative-free, ready-to-administer sterile presentation with strong hospital distribution is the most commercially credible concept. Its value would depend on demonstrated stability, pharmacy workflow benefits, and sufficient market volume.

References

1. U.S. Food and Drug Administration. (2019). Corvert (ibutilide fumarate) injection prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.